Congenital TORCH Infections Linked to Significantly Higher Risk of Autism and Intellectual Disability

Children born with specific congenital infections grouped under the acronym TORCH are approximately three times more likely to receive an autism diagnosis compared to uninfected peers, according to a large-scale population study published in JAMA Pediatrics. The investigation, conducted by researchers at the Karolinska Institutet in Stockholm, tracked nearly 3.7 million individuals born in Sweden from 1987 through 2021, representing the most comprehensive evaluation of its kind to date.

According to PubMed / Human Vaccines & Immunotherapeutics, vaccine candidates progressed from 1970s live-attenuated strains (Towne) and a 2009 Phase 2 gB subunit vaccine to mRNA platforms in the 2020s, notably Moderna's mRNA-1647 evaluating gB and pentamer antigens in the Phase 3 CMVictory trial. According to Centers for Disease Control and Prevention, following the introduction of rubella vaccines in 1969 and universal childhood immunization, endemic rubella and congenital rubella syndrome transmission was declared eliminated in the United States in 2004.

TORCH encompasses a collection of pathogens capable of crossing the placenta during pregnancy, including toxoplasmosis, rubella, cytomegalovirus (CMV), and herpes simplex virus. Among the 975 study participants diagnosed with a congenital TORCH infection at birth, researchers observed a markedly elevated risk for severe neurodevelopmental outcomes that persisted even after adjusting for sibling cohorts to control for shared genetic and familial confounding factors.

Neurodevelopmental Risk and Sibling Adjustments

The research team found that while relative risks were striking, congenital TORCH infections account for only a small fraction of overall autism cases across the broader population because the conditions remain rare at birth. Specifically, authors estimated that these prenatal exposures account for roughly 0.034 percent of autism cases in Sweden. At the individual level, however, the data suggest that approximately one in five children born with a diagnosed TORCH infection may develop autism over time.

According to Centers for Disease Control and Prevention, for Centers for Disease Control and Prevention, The CDC advises pregnant women to lower their risk of CMV by reducing contact with saliva and urine from young children, specifically not sharing food, utensils, cups, or pacifiers, and washing hands with soap and water after diaper changes.

In contrast to findings regarding autism, the study identified no clear statistical association between congenital TORCH infections and other neuropsychiatric conditions such as attention-deficit/hyperactivity disorder or obsessive-compulsive disorder. The absence of these links helps narrow the specific cognitive pathways influenced by early viral or parasitic exposures during fetal development.

Severe Intellectual Disability and Academic Impact

The association between congenital TORCH infections and intellectual disability proved even more pronounced than the autism findings. Affected children were more than seven times more likely to be diagnosed with an intellectual disability than uninfected peers, with the risk of severe to profound intellectual disability increasing by up to 30 times.

Researchers calculated that these prenatal infections may account for approximately 1.2 percent of severe intellectual disability cases in Sweden. Furthermore, academic performance evaluations revealed that affected children received lower average grades later in life, including individuals who never received a formal clinical diagnosis of autism or intellectual disability, pointing toward more subtle cognitive differences.

Cytomegalovirus Prevalence and Prevention Calls

Cytomegalovirus accounted for roughly half of all observed TORCH cases in the study cohort. Experts not involved in the research noted that while the CMV-autism link has been suspected for decades, previous investigations were often small and uncontrolled, making the Karolinska Institutet findings a significant milestone in establishing clinical rigor.

Mark Schleiss, a pediatric infectious disease physician at the University of Minnesota School of Medicine, argued that the findings reinforce the critical need for expanded immunizations and screening policies. Schleiss emphasized that public awareness of CMV remains low and pointed to legislative efforts in the United States, including the Stop CMV Act, which seeks to mandate newborn screening nationwide alongside existing state programs in Minnesota and Connecticut.

According to Reviews in Medical Virology, in 1999–2000, the Institute of Medicine designated the development of a cytomegalovirus vaccine as a Level I (highest priority) candidate in its Vaccines for the 21st Century report due to substantial disease burden and cost-effectiveness. According to BMJ Paediatrics Open, for preventive hygiene measures, Public health recommendations emphasize behavioral modifications around toddlers, including kissing children on the head or forehead rather than the lips and cleaning surfaces and toys that come into contact with bodily fluids.

Public Health Translations and Screening Limitations

External epidemiologists cautioned that translating Swedish registry findings to other nations requires careful consideration of local demographics and public-health practices. Lisa Croen, an epidemiologist at Kaiser Permanente, noted that screening protocols and baseline infection rates vary widely between Scandinavia and North America.

Megan Pesch, medical director of the Center for Autism and Developmental Disabilities at Henry Ford Health, added that the study focused exclusively on clinically identified TORCH infections. As a result, children with asymptomatic congenital infections may not be captured in the risk estimates, suggesting that actual population impacts could differ depending on clinical detection practices and routine prenatal screening standards.